RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS)

被引：0
|
作者：
Garcia-Manero, G. [1 ]
Fenaux, P. [2 ]
Al-Kali, A. [3 ]
Baer, M. R. [4 ]
Sekeres, M. [5 ]
Roboz, G. [6 ]
Gaidano, G. [7 ]
Scott, B. [8 ]
Greenberg, P. [9 ]
Platzbecker, U. [10 ]
Steensma, D. P. [11 ]
Kambhampati, S. [12 ]
Kreuzer, K. A. [13 ]
Godley, L. [14 ]
Collins, R. [15 ]
Atallah, E. [16 ,17 ]
Azarnia, N. [18 ]
Petrone, M. E. [19 ]
Snyder, B. R. [20 ]
Maniar, M. [21 ]
Silverman, L. R. [22 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Hosp St Louis, Serv Hematol Seniors, Paris, France
[3] Mayo Clin, Dept Hematol, Rochester, MN USA
[4] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
[5] Cleveland Clin, Dept Hematol Oncol & Blood Disorders, Cleveland, OH 44106 USA
[6] Weill Cornell Med Coll, Leukemia Serv, New York, NY USA
[7] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Novara, Italy
[8] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA
[9] Stanford Med Sch, Dept Med Hematol, Stanford, CA USA
[10] Univ Klinikum Dresden, Med Klin & Poliklin 1, Dresden, Germany
[11] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[12] Univ Kansas, Med Ctr, Dept Internal Med, Westwood, KS USA
[13] Univ Klinikum Koln, Dept Internal Med, Cologne, Germany
[14] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA
[15] Univ Texas Dallas, Dept Internal Med, Dallas, TX 75230 USA
[16] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Div Hematol & Oncol, Milwaukee, WI 53226 USA
[17] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[18] Onconova Therapeut Inc, Dept Biometr, Newtown, PA USA
[19] Onconova Therapeut Inc, Dept Pharmacovigilance & Med & Sci Commun, Newtown, PA USA
[20] Onconova Therapeut Inc, Dept Med & Sci Commun, Newtown, PA USA
[21] Onconova Therapeut Inc, Prod Dev Dept, Newtown, PA USA
[22] Icahn Sch Med Mt Sinai, Dept Leukemia, New York, NY 10029 USA
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30113-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
112
引用
收藏
页码：S57 / S58
页数：2
相关论文
共 50 条
  • [21] Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Zeidan, Amer M.
    Ando, Kiyoshi
    Rauzy, Odile
    Turgut, Mehmet
    Wang, Ming-Chung
    Cairoli, Roberto
    Hou, Hsin-An
    Kwong, Yok-Lam
    Sangerman, Montserrat Arnan
    Meers, Stef
    Pullarkat, Vinod A.
    Santini, Valeria
    Malek, Kamel
    Kiertsman, Flavia
    Lyu, Jiaying
    Ramos, Pedro Marques
    Fenaux, Pierre
    Miyazaki, Yasushi
    Platzbecker, Uwe
    BLOOD, 2022, 140 : 2063 - 2065
  • [22] Evaluation of International Working Group 2006 Response Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agent Monotherapy in the Frontline Setting
    Bewersdorf, Jan Philipp
    Wei, Wei
    Jaiani, Anna
    Patel, Prital
    Mehta, Rajni
    Neparidze, Natalia
    Shallis, Rory M.
    Podoltsev, Nikolai
    Brunner, Andrew M.
    Zeidan, Amer M.
    BLOOD, 2021, 138 : 3701 - +
  • [23] Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis
    Bewersdorf, Philipp
    Kewan, Tariq
    Blaha, Ondrej
    Stahl, Maximilian
    Al Ali, Najla H.
    DeZern, Amy E.
    Sekeres, Mikkael A.
    Uy, Geoffrey L.
    Carraway, Hetty E.
    Desai, Pinkal
    Griffiths, Elizabeth A.
    Stein, Eytan M.
    Brunner, Andrew M.
    McMahon, Christine M.
    Zeidner, Joshua F.
    Savona, Michael R.
    Stempel, Jessica M.
    Chandhok, Namrata Sonia
    Ramaswamy, Rahul
    Roboz, Gail J.
    Rolles, Benjamin
    Wang, Eunice S.
    Harris, Amyah C.
    Amaya, Maria L.
    Hawkins, Hayley
    Grenet, Justin
    Gurnari, Carmelo
    Shallis, Rory M.
    Xie, Zhuoer
    Maciejewski, Jaroslaw P.
    Sallman, David A.
    Della Porta, Matteo Giovanni
    Komrokji, Rami S.
    Zeidan, Amer M.
    BLOOD, 2023, 142
  • [24] Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study
    Brunner, Andrew
    Borate, Uma
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Vey, Norbert
    Scholl, Sebastian
    Wermke, Martin
    Janssen, Jeroen
    Traer, Elie
    Chua, Chong Chyn
    Narayan, Rupa
    Tovar, Natalia
    Kontro, Mika
    Ottman, Oliver
    Xu, Siyan
    Sun, Haiying
    Naidu, Purushotham
    Szpakowski, Sebastian
    Zhang, Na
    Mohammed, Anisa
    Rinne, Mikael
    Wei, Andrew
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S188 - S189
  • [25] Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients.
    Silverman, Lewis R.
    Fenaux, Pierre
    Al-Kali, Aref
    Baer, Maria R.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    Gaidano, Gianluca
    Scott, Bart L.
    Greenberg, Peter
    Platzbecker, Uwe
    Steensma, David P.
    Kreuzer, Karl A.
    Godley, Lucy A.
    Collins, Robert
    Atallah, Ehab L.
    Azarnia, Nozar
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
    Garcia-Manero, Guillermo
    Fenaux, Pierre
    Al-Kali, Aref
    Baer, Maria R.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    Gaidano, Gianluca
    Scott, Bart L.
    Greenberg, Peter
    Platzbecker, Uwe
    Steensma, David P.
    Kambhampati, Suman
    Kreuzer, Karl-Anton
    Godley, Lucy A.
    Atallah, Ehab
    Collins, Robert, Jr.
    Kantarjian, Hagop
    Jabbour, Elias
    Wilhelm, Francois E.
    Azarnia, Nozar
    Silverman, Lewis R.
    LANCET ONCOLOGY, 2016, 17 (04): : 496 - 508
  • [27] Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
    Garcia-Manero, Guillermo
    Jonasova, Anna
    Luger, Selina M.
    Al-Kali, Aref
    Valcarcel, David
    Warlick, Erica D.
    Jedrzejczak, Wieslaw W.
    Diez-Campelo, Maria
    Zbyszewski, Patrick S.
    Cavanaugh, Christopher
    Woodman, Richard C.
    Fruchtman, Steven M.
    Takahashi, Koichi
    BLOOD, 2019, 134
  • [28] ECONOMIC IMPACT AND HEALTHCARE UTILIZATION IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS) IN ROUTINE CLINICAL CARE IN THE UNITED STATES (US) - A CLAIMS DATABASE STUDY
    Bell, J.
    Galaznik, A.
    Farrelly, E.
    Blazer, M.
    Shih, H. -C.
    Raju, A.
    Ogbonnaya, A.
    Eaddy, M.
    Fram, R.
    Faller, D.
    HAEMATOLOGICA, 2017, 102 : 486 - 486
  • [29] Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib plus Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)
    Garcia-Manero, Guillermo
    Navada, Shyamala C.
    Fenaux, Pierre
    Zbyszewski, Patrick S.
    Adesanya, Afoluso Ronnee
    Azarnia, Nozar
    Fruchtman, Steven M.
    Silverman, Lewis R.
    BLOOD, 2019, 134
  • [30] A RANDOMIZED STUDY OF DECITABINE ALTERNATING WITH CLOFARABINE VERSUS DECITABINE ALONE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Faderl, S.
    Garcia-Manero, G.
    Kadia, T.
    Borthakur, G.
    Jabbour, E.
    Ravandi, F.
    Estrov, Z.
    Cortes, J.
    Autry, J.
    Kantarjian, H.
    HAEMATOLOGICA, 2012, 97 : 369 - 369
12345